Omalizumab as single-dose therapy for vernal keratoconjunctivitis.

Simpson, Rachel S; Lee, Jason K

Simpson, Rachel S; Lee, Jason K.

Simpson RS; Division of Life Sciences, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada; Evidence Based Medical Educator Inc, Toronto, Ontario, Canada. Electronic address: rachel.simpson@queensu.ca.
Lee JK; Evidence Based Medical Educator Inc, Toronto, Ontario, Canada; Canadian Society of Allergy and Clinical Immunology, Orleans, Ontario, Canada.

Ann Allergy Asthma Immunol ; 122(1): 119-120, 2019 01.

Article en En | MEDLINE | ID: mdl-30243989

Asunto(s)

Antialérgicos/uso terapéutico; Conjuntivitis Alérgica/tratamiento farmacológico; Queratoconjuntivitis/tratamiento farmacológico; Omalizumab/uso terapéutico; Conjuntivitis Alérgica/inmunología; Ciproheptadina/análogos & derivados; Ciproheptadina/uso terapéutico; Humanos; Inmunoglobulina E/inmunología; Queratoconjuntivitis/inmunología; Masculino; Persona de Mediana Edad; Clorhidrato de Olopatadina/uso terapéutico

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Conjuntivitis Alérgica / Antialérgicos / Omalizumab / Queratoconjuntivitis Límite: Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google